メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
臨床薬剤科
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(7)
研究成果
(105)
フィンガープリント
臨床薬剤科が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Antipsychotic
88%
Disease
82%
Polypharmacy
77%
Cisplatin
76%
Randomized Controlled Trial
67%
Adverse Drug Reaction
67%
Combination Therapy
67%
Aripiprazole
61%
Histone
57%
Acute Lung Injury
57%
Recurrent Disease
57%
Symptom
47%
Cohort Study
46%
Chemotherapy
44%
Typical Antipsychotic
43%
Immune Checkpoint Inhibitor
43%
Observational Study
42%
SARS Coronavirus
41%
Lung Cancer
40%
Clozapine
40%
Thrombocytopenia
39%
Favipiravir
38%
Interstitial Lung Disease
38%
Cancer Chemotherapy
38%
Vaccination Policy
38%
Treatment-Resistant Schizophrenia
38%
Colorectal Cancer
38%
Nivolumab
37%
Retrospective Study
36%
Placebo
36%
Remission
34%
Malignant Neoplasm
31%
Monotherapy
31%
Coronavirinae
31%
Rituximab
30%
Major Depression
28%
Chronic Kidney Failure
28%
Toxic Injury
28%
Sepsis
28%
Receptor
28%
Anticarcinogen
26%
Acute Kidney Failure
24%
Allergic Reaction
24%
Risperidone
23%
Paliperidone
23%
Tolerability
22%
Dexamethasone
22%
Infection
21%
Diazepam
21%
Benzodiazepine
21%
Prescription Drug
21%
Aspartate Aminotransferase
21%
Clinical Trial
20%
Fluorouracil
20%
Depression
19%
Mouse
19%
Ifosfamide
19%
Second-Line Chemotherapy
19%
Recurrence Risk
19%
Lamictal
19%
Bipolar I Disorder
19%
Drug Administration
19%
Phenylenediamine
19%
Ascorbic Acid
19%
Intraocular Hemorrhage
19%
Anemia
19%
Vertebral Canal Stenosis
19%
Asenapine
19%
Blood Toxicity
19%
Breast Cancer
19%
Hyperuricemia
19%
Nephrotoxicity
19%
CD20 Antibody
19%
Musculoskeletal Disease
19%
Thiamine
19%
Antianemic Agent
19%
Headache
19%
High Density Lipoprotein Cholesterol
19%
Nonhodgkin Lymphoma
19%
Bendamustine
19%
Stomach Cancer
19%
Hydrocortisone
19%
Syndrome
19%
Uric Acid
19%
Naldemedine
19%
Diffuse Large B Cell Lymphoma
19%
Immunoglobulin G Antibody
19%
Carboplatin
19%
Immunoglobulin A Nephropathy
19%
Febrile Neutropenia
19%
Antidepressant
19%
Bipolar Mania
19%
Olanzapine
19%
Cytomegalovirus
19%
Hemoglobin A1c
19%
Fragility Fracture
19%
Limb Fracture
19%
Population Study
19%
Glucocorticoid
19%
Keyphrases
Favipiravir
38%
Japanese Adverse Drug Event Report (JADER)
38%
Drug-induced Interstitial Lung Disease
38%
Chemotherapy
24%
Immune Checkpoint Inhibitors
24%
Japan
24%
Disease Control
24%
Confidence Interval
23%
Antipsychotics
22%
Nivolumab
22%
Vortioxetine
21%
Monotherapy
21%
COVID-19
20%
Second-line Chemotherapy
19%
Subjective Survey
19%
Online Team-based Learning
19%
Long-acting Injection
19%
Hair Color
19%
Lamotrigine
19%
Enrichment Design
19%
Clozapine
19%
Perm
19%
P-phenylenediamine
19%
Early Dialysis
19%
Trends Survey
19%
Intraocular Hemorrhage
19%
Renal Hypoperfusion
19%
Pressure-induced
19%
Coagulation Pathway
19%
L-OHP
19%
Steady State
19%
Nontechnical Skills for Surgeons
19%
Hyperuricemia
19%
Kaizen
19%
Bundled Interventions
19%
Drug Survey
19%
Hematopoietic Function
19%
Relapsed Lymphoma
19%
CBDCA
19%
Combination of Therapies
19%
Machine Learning Software
19%
Older People
19%
Newer Antidepressants
19%
Long-acting Injectable Aripiprazole
19%
Muscle Injection
19%
5-fluorouracil (5-FU)
19%
Deltoid Injection
19%
COVID-19 Patients
19%
Sodium Zirconium Cyclosilicate
19%
Interstitial Lung Disease
19%
HAT Therapy
19%
Major Depressive Disorder
19%
Pharmaceutical Consultation
19%
MRNA Vaccine
19%
Anticancer Drugs
19%
Uric Acid
19%
IgA Nephropathy (IgAN)
19%
Short-acting
19%
Ocular Side Effects
19%
Febrile Neutropenia
19%
Tolerability
19%
Bipolar Mania
19%
Risk Degree
19%
Extremity Fractures
19%
Older Surgical Patients
19%
Antipsychotic Polypharmacy
19%
Post-hoc Explanation
19%
Work Outcomes
19%
Mirror-image Study
19%
Failure Mode Effect Analysis
19%
Opioid Rotation
19%
IgA Antibody
19%
Nontuberculous Mycobacterial Lung Disease
19%
Lupus Nephritis
19%
Cause-effect Analysis
19%
Antidepressants
19%
Fat Emulsion
19%
Elderly Female Patients
19%
Medication Pattern
19%
Fracture Risk Assessment
19%
Early Palliative Care
19%
Patients with Schizophrenia
19%
Systematic Meta-analysis
19%
Fosaprepitant
19%
Aprepitant
19%
Neutrophil-lymphocyte Ratio
19%
Meta-analysis
19%
Cisplatin
19%
Treatment-resistant Schizophrenia
19%
SLC47A1
19%
Gastric Cancer
19%
Secondary Pulmonary Hypertension
19%
Cancer-associated Thrombosis
19%
Nontuberculous Mycobacteriosis
19%
Treatment-resistant Depression
19%
Anti-endothelial Cell Antibodies
16%
Team-based Learning
16%
Readiness Assurance Test
16%
Left DLPFC
16%
MATE1
16%
Medicine and Dentistry
Elderly Patient
24%
Odds Ratio
24%
Disease
23%
Patient Safety
23%
Nivolumab
22%
Prescription Drug
21%
Outpatient
21%
Spinal Stenosis
19%
Favipiravir
19%
Retrospective Study
19%
Neutrophil
19%
Phenylenediamine
19%
Blood Toxicity
19%
Stomach Cancer
19%
Extracellular Trap
19%
End Stage Renal Disease
19%
RNA
19%
Urothelial Cancer
19%
Sodium Zirconium Cyclosilicate
19%
Symptomatic Treatment
19%
Lung Cancer
19%
Interstitial Lung Disease
19%
Computer Assisted Tomography
19%
Thrombocytopenia
19%
Cisplatin
19%
Combination Therapy
19%
Obsessive Compulsive Disorder
19%
5-HT3 Antagonist
19%
Yale-Brown Obsessive Compulsive Scale
19%
Overall Survival
19%
Operation Duration
19%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Clinical Trial
19%
Limb Fracture
19%
Naldemedine
19%
Second-Line Chemotherapy
19%
Histone
19%
Acute Lung Injury
19%
Polypharmacy
19%
Surgeon
19%
Lupus Nephritis
19%
Lipid Emulsion
19%
Immunoglobulin A Antibody
19%
Febuxostat
19%
Diabetic Nephropathy
19%
Anaphylaxis
19%
Senescence
19%
Physical Performance
19%
Surgery
19%
Logistic Regression Analysis
19%
Open Lung Biopsy
19%
Pemetrexed
19%
Patient with Psychiatric Disorder
19%
CD11b Antigen
19%
Immune Checkpoint Inhibitor
19%
Contrast Medium
19%
Cancer Chemotherapy
19%
Gemcitabine
19%
Mycobacteriosis
19%
Capecitabine Plus Oxaliplatin
19%
Diagnosis
15%
Endothelial Cell Antibody
13%
Platelet
13%
Placebo
12%
mRNA Vaccine
12%
Injection
11%
Esomeprazole
11%
Quality Improvement
10%
Psychiatric Treatment
9%
Multivariate Analysis
8%
Progressive Disease
8%
Patient Referral
7%
Spine Surgery
7%
Hand Grip
7%
Body Mass Index
7%
Vonoprazan
7%
Atezolizumab
7%
Leukocyte
6%
Cancer of Unknown Primary Origin
6%
Gastrectomy
6%
Lower Anterior Resection
6%
Herniorrhaphy
6%
Cellular Immunity
6%
Total Stomach Resection
6%
Colectomy
6%
Receptor Binding
6%
Rectum Anterior Resection
6%
Mycobacteria
6%
Adverse Event
6%
Drug Therapy
5%
Cysteamine
5%
Skin Allergy
5%
Contact Allergy
5%
Obsession
5%
Immune-Related Adverse Events
5%
Mass Immunization
5%
COVID-19
5%